# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Robert Burns reiterates SpringWorks Therapeutics (NASDAQ:SWTX) with a Buy and maintains $74 ...
SpringWorks Therapeutics (NASDAQ:SWTX) reported quarterly losses of $(1.18) per share which missed the analyst consensus estima...
HC Wainwright & Co. analyst Robert Burns maintains SpringWorks Therapeutics (NASDAQ:SWTX) with a Buy and raises the pric...
JP Morgan analyst Anupam Rama maintains SpringWorks Therapeutics (NASDAQ:SWTX) with a Overweight and raises the price target...
Barclays analyst Peter Lawson maintains SpringWorks Therapeutics (NASDAQ:SWTX) with a Overweight and raises the price target...